You are here:
Characterization of biomarkers for the prediction of response to SAHA in B-cell lymphoma
The therapy of aggressive B-cell lymphoma could be significantly improved by the use of the therapeutic CD20 antibody rituximab, but unfortunately approximately 50% of patients can not be treated adequately. Therefore, the search for improved therapies is a primary goal. Previous studies have shown evidence that epigenetic features may be associated with the clinical course of B-cell lymphoma. For this reason, influence of the epigenetic profiles of tumor cells, particularly in combination with standard chemotherapy, can be an alternative therapeutic approach.
SAHA (Vorinostat, Zolinza®) is now approved for the treatment of cutaneous T-cell lymphoma and in individual B-cell lymphoma patients a complete response was observed by SAHA monotherapy. The aim of the project is to identify biomarkers of "companion diagnostics" to identify appropriate B-cell lymphoma patients for the treatment with the histone deacetylase inhibitor SAHA.
Joosten, M., et al., A novel approach to detect resistance mechanisms reveals FGR as a factormediating HDAC inhibitor SAHA resistance in B-cell lymphoma, Molecular Oncology (2016); PMID: 27324824